Elusive antidotes: progress developing chemical, biological, radiological, and nuclear countermeasures : hearing before the Subcommittee on National Security, Emerging Threats, and International Relations of the Committee on Government Reform, House of Representatives, One Hundred Ninth Congress, first session, June 14, 2005, Volume 4U.S. Government Printing Office, 2005 - 131 pages |
Autres éditions - Tout afficher
Expressions et termes fréquents
anthrax toxins anthrax vaccine antibodies Biodefense Research Biological Defense Program biological warfare biological warfare agents bioterrorism botulinum toxin botulism CBRN Threats June14 Chairman Chemical and Biological clinical trials CONGRES CONGRESS THE LIBRARY contract coordination countermeasures against biological DAVIS Department of Defense Department of Homeland develop medical countermeasures development and acquisition development of medical doses drugs Efforts June 14 Emerging Threats Fauci Federal funding GRESS HANNA Health and Human HHS Preparedness Efforts Homeland Security Human Genome Sciences Human Services Infectious Diseases interagency June 14 JVAP KLEIN LIBRARY OF CONGRESS manufacturing MARCHANT material threat medical countermeasures million National Security NIAID NIH Biomedical Research Preparedness Efforts June priority procurement Project BioShield Project Bioshield Act public health Radiological and Nuclear RARY Research Agenda research and development Research in Responding Responding to CBRN response risk assessments Role of NIH scientific SHAYS Strategic National Stockpile
Fréquemment cités
Page 54 - HHS, along with representatives from the Department of Homeland Security (DHS) and the Department of Defense (DoD), co-chairs the WMDMC Subcommittee and stakeholders from throughout the USG are represented on it.
Page 54 - P»g* 3 53 having the greatest potential to cause catastrophic harm. A sense of urgency has pervaded our efforts and we have defined new ways of doing business. Our new national security environment demands accelerated product development timelines and new paradigms of interactions between industry and government with increased risk-sharing and enhanced intra-governmental collaboration.
Page 121 - House Subcommittee on National Security, Emerging Threats and International Relations Committee on Government Reform US House of Representatives Hearing on "Nuclear Security: Has the NRC Strengthened Facility Standards Since 9/11?
Page 77 - Research Council is the operating arm of the National Academy of Sciences, National Academy of Engineering, and the Institute of Medicine of the National Academies, chartered by Congress in 1863 to advise the government on matters of science and technology.
Page 60 - Product delivery began last month and should be completed by the end of the fiscal year. Ongoing Project BioShield activities. In addition to the acquisition contracts that have been awarded since enactment of Project BioShield, there are several other important BioShield procurementrelated activities underway. We are engaged in contract negotiations for anthrax therapies, and we are continuing to move forward on the acquisition of an antitoxin treatment for botulism. Furthermore, HHS has moved forward...
Page 51 - Assistant Secretary for Public Health Emergency Preparedness, Department of Health and Human Services (HHS). I appreciate the opportunity to share with you information on the Department's...
Page 76 - Testimony Before the Subcommittee on National Security, Emerging Threats, and International Relations, Committee on Government Reform, House of Representatives...
Page 27 - Finally, immunological studies of the human innate immune system, which is comprised of broadly active "first responder" cells and other mechanisms that are the first line of defense against infection, have been moving forward rapidly.
Page 60 - RFI to assess the state of development of therapeutics for acute radiation syndrome. Finally, in anticipation of yet to be determined requirements, we actively monitor the state of the medical countermeasure pipeline — both within and outside the government — by evaluating USG research and development portfolios and engaging industry through the publication of Requests for Information (RFIs). For example, we have recently released three RFIs to assess the timeline to maturity of medical cpuntermeasures...